Infusion Therapy Center
Reliable treatments for better wellness.
REGEN-COV Infusion for Treatment
Regeneron EUA Information for Patients
The Emergency Use Authorization (EUA) allows REGEN-COV infusion for the treatment of mild to moderate COVID-19 in adult and pediatric patients (12 years and older, weighing at least 40 kg) who:
Have a positive SARS-CoV-2 viral test
Are at high risk for progression to severe COVID-19, including hospitalization or death
Eligibility Requirements
You Must Meet All of the Following Criteria:
Positive SARS-CoV-2 test
Within 10 days of initial symptom onset
Age 12 years or older
Weight at least 88 lbs (40 kg)
Oxygen saturation (SpO2) ≥94%
And at Least One of the Following Risk Factors:
Age 65 years or older
BMI >25 kg/m² (or age 12–17 with BMI ≥85th percentile)
Chronic kidney disease
Diabetes
Immunosuppressive disease or immunosuppressive treatment
Cardiovascular disease (including congenital heart disease) or hypertension
Chronic lung disease (COPD, moderate to severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension)
Sickle cell disease
Neurodevelopmental disorders (e.g., cerebral palsy), genetic or metabolic syndromes, or severe congenital anomalies
Medical-related technological dependence (e.g., tracheostomy or gastrostomy)
Important Notice
OB approval is required if the patient is pregnant.